STOCK TITAN

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Elutia (ELUT) granted 378,000 stock options to two new employees on November 10, 2026, as inducements to join the company.

The non-qualified options have an exercise price of $0.93 per share, equal to the stock’s closing price on the grant date. They vest 25% on the first anniversary of their vesting commencement dates, with the balance vesting monthly over the following three years, subject to continued employment. The independent Compensation Committee approved the awards under the 2026 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.378,000 employee stock options at a $0.93 exercise price create potential dilution upon exercise.

Key Figures

Inducement options: 378,000 non-qualified stock options Exercise price: $0.93 per share Vesting schedule: 25% on the first anniversary; balance in equal monthly installments over the following three years
Inducement options
378,000 non-qualified stock options
Granted to two new employees under the 2026 Inducement Award Plan
Exercise price
$0.93 per share
Grant date: November 10, 2026
Vesting schedule
25% on the first anniversary; balance in equal monthly installments over the following three years
Subject to continued employment through each applicable vesting date

Key Terms

non-qualified stock options
1 terms
non-qualified stock options financial
"aggregate of 378,000 non-qualified stock options"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

GAITHERSBURG, Md., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a drug delivery company built to stop surgical infections, today announced that it granted equity awards on November 10, 2026 to two new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”). The awards were approved by the independent Compensation Committee of the Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Under the Plan, the two new employees received an aggregate of 378,000 non-qualified stock options (the “Options”). The Options vest 25% on the first anniversary of their vesting commencement dates, with the balance vesting in equal monthly installments over the following three years. Vesting is subject to each recipient’s continued employment through the applicable vesting date. The Options had an exercise price of $0.93 per share, the closing price of Elutia’s common stock on the Nasdaq Capital Market on November 10, 2026, the grant date. The Options are subject to the terms and conditions of the Plan and the applicable stock option agreement.

About Elutia
Elutia Inc. (Nasdaq: ELUT) is a drug delivery company built to stop surgical infections. The Company developed and launched EluPro, the first antibiotic-eluting bioenvelope designed to protect patients receiving pacemakers and defibrillators, and in 2025 sold that business to Boston Scientific Corporation. Elutia’s lead program, NXT-41x, builds on the same drug-eluting platform and is designed to deliver two powerful antibiotics directly to the surgical site, stopping infection before it starts. Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Elutia Investor Relations
ir@elutia.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employee inducement awards did Elutia grant on November 10, 2026?

Elutia granted two new employees an aggregate of 378,000 non-qualified stock options with an exercise price of $0.93 per share, equal to the closing stock price on the grant date.

What is the vesting schedule for Elutia’s employee inducement options?

The options vest 25% on the first anniversary of their vesting commencement dates, with the balance vesting in equal monthly installments over the following three years. Each recipient must remain employed through the applicable vesting date.

Keep reading